Search Results - "De Bruyn, Marco"

Tumor-infiltrating lymphocytes in the immunotherapy era by Paijens, Sterre T., Vledder, Annegé, de Bruyn, Marco, Nijman, Hans W.

“…The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention on tumor-infiltrating lymphocytes (TILs) across cancer types. The…”
Get full text

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients by Horeweg, Nanda, Workel, Hagma H., Loiero, Dominik, Church, David N., Vermij, Lisa, Léon-Castillo, Alicia, Krog, Ricki T., de Boer, Stephanie M., Nout, Remi A., Powell, Melanie E., Mileshkin, Linda R., MacKay, Helen, Leary, Alexandra, Singh, Naveena, Jürgenliemk-Schulz, Ina M., Smit, Vincent T. H. B. M., Creutzberg, Carien L., Koelzer, Viktor H., Nijman, Hans W., Bosse, Tjalling, de Bruyn, Marco

“…B-cells play a key role in cancer suppression, particularly when aggregated in tertiary lymphoid structures (TLS). Here, we investigate the role of B-cells and…”
Get full text

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties by Vlaming, Martijn, Bilemjian, Vrouyr, Freile, Jimena Álvarez, Lourens, Harm Jan, van Rooij, Nienke, Huls, Gerwin, van Meerten, Tom, de Bruyn, Marco, Bremer, Edwin

“…The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various…”
Get full text

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis by He, Yuan, Bouwstra, Renee, Wiersma, Valerie R., de Jong, Mathilde, Jan Lourens, Harm, Fehrmann, Rudolf, de Bruyn, Marco, Ammatuna, Emanuele, Huls, Gerwin, van Meerten, Tom, Bremer, Edwin

“…CD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies currently being evaluated in clinical trials. For effective evaluation of…”
Get full text

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition by Eggink, Florine A., Van Gool, Inge C., Leary, Alexandra, Pollock, Pamela M., Crosbie, Emma J., Mileshkin, Linda, Jordanova, Ekaterina S., Adam, Julien, Freeman-Mills, Luke, Church, David N., Creutzberg, Carien L., De Bruyn, Marco, Nijman, Hans W., Bosse, Tjalling

“…High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic options are needed. Aims of this study were to validate the enhanced…”
Get full text

672 Induction of specific T-cell responses to tumor associated antigens and induction of B-cell responses in ovarian cancer patients by intradermal injection of vididencel by Vledder, Annege, Zeeburg, Hester Van, Singh, Satwinder, Rovers, Jeroen, Bruyn, Marco de, Nijman, Hans

“…BackgroundTreatment of high grade serous ovarian cancer (HGSOC) after debulking and chemotherapy remains challenging. This phase 1 trial (NCT04739527)…”
Get full text

Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats by Wei, Yunwei, Chen, Ping, de Bruyn, Marco, Zhang, Weihui, Bremer, Edwin, Helfrich, Wijnand

“…Hepatic ischemia-reperfusion injury (I/Ri) is a serious complication occurring during liver surgery that may lead to liver failure. Hepatic I/Ri induces…”
Get full text

Development of [89Zr]Zr-hCD103.Fab01A and [68Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET by Fan, Xiaoyu, Ważyńska, Marta A., Kol, Arjan, Perujo Holland, Noemi, Fernandes, Bruna, van Duijnhoven, Sander M. J., Plat, Annechien, van Eenennaam, Hans, Elsinga, Philip H., Nijman, Hans W., de Bruyn, Marco

“…Background CD103 is an integrin specifically expressed on the surface of cancer-reactive T cells. The number of CD103+ T cells significantly increases during…”
Get full text

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo by de Bruyn, Marco, Rybczynska, Anna A, Wei, Yunwei, Schwenkert, Michael, Fey, Georg H, Dierckx, Rudi A J O, van Waarde, Aren, Helfrich, Wijnand, Bremer, Edwin

“…Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited patient survival of ~6 - 9 months. Here, we report on a novel…”
Get full text

171 Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer by Nagasawa, Maho, Bos, Remco, Zuo, Haoxiao, Wang Yin, Kiave Yune Ho, Lierop, Marie-José van, Tabruyn, Sebastien, Manting, Erik, Bruyn, Marco de, Nijman, Hans, Singh, Satwinder KAur, Singh, Satwinder Kaur

“…BackgroundOvarian cancer (OC) is the gynecological malignancy with the highest mortality due to the late diagnosis of disease and a high rate of relapse…”
Get full text

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy by León-Castillo, Alicia, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda R, Mackay, Helen J, Leary, Alexandra, Nijman, Hans W, Singh, Naveena, Pollock, Pamela M, Bessette, Paul, Fyles, Anthony, Haie-Meder, Christine, Smit, Vincent T H B M, Edmondson, Richard J, Putter, Hein, Kitchener, Henry C, Crosbie, Emma J, de Bruyn, Marco, Nout, Remi A, Horeweg, Nanda, Creutzberg, Carien L, Bosse, Tjalling

“…The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of…”
Get full text

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells by Stutvoet, Thijs S, Kol, Arjan, Vries, Elisabeth GE, Bruyn, Marco, Fehrmann, Rudolf SN, Terwisscha van Scheltinga, Anton GT, Jong, Steven

“…Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with…”
Get full text

Therapeutic potential of Galectin-9 in human disease by Wiersma, Valerie R., de Bruyn, Marco, Helfrich, Wijnand, Bremer, Edwin

“…In recent years, an important role has emerged for the glycan‐binding protein Galectin‐9 (Gal‐9) in health and disease. In normal physiology, Gal‐9 seems to be…”
Get full text

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer by van Gool, Inge C, Eggink, Florine A, Freeman-Mills, Luke, Stelloo, Ellen, Marchi, Emanuele, de Bruyn, Marco, Palles, Claire, Nout, Remi A, de Kroon, Cor D, Osse, Elisabeth M, Klenerman, Paul, Creutzberg, Carien L, Tomlinson, Ian Pm, Smit, Vincent Thbm, Nijman, Hans W, Bosse, Tjalling, Church, David N

“…Recent studies have shown that 7% to 12% of endometrial cancers are ultramutated due to somatic mutation in the proofreading exonuclease domain of the DNA…”
Get full text

Genomic instability as a driver and suppressor of anti-tumor immunity by Requesens, Marta, Foijer, Floris, Nijman, Hans W., de Bruyn, Marco

“…Genomic instability is a driver and accelerator of tumorigenesis and influences disease outcomes across cancer types. Although genomic instability has been…”
Get full text

Antibody-based fusion proteins to target death receptors in cancer by de Bruyn, Marco, Bremer, Edwin, Helfrich, Wijnand

“…Abstract Ideally, an immunotoxin should be inactive ‘en route’, acquire activity only after tumor cell surface binding and have no off-target effects towards…”
Get full text

CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer by Komdeur, Fenne L., Prins, Thalina M., van de Wall, Stephanie, Plat, Annechien, Wisman, G. Bea A., Hollema, Harry, Daemen, Toos, Church, David N., de Bruyn, Marco, Nijman, Hans W.

“…Human papilloma virus (HPV)-induced cervical cancer constitutively expresses viral E6/E7 oncoproteins and is an excellent target for T cell-based…”
Get full text

Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma by Krämer, Pauline, Talhouk, Aline, Brett, Mary Anne, Chiu, Derek S, Cairns, Evan S, Scheunhage, Daniëlla A, Hammond, Rory F L, Farnell, David, Nazeran, Tayyebeh M, Grube, Marcel, Xia, Zhouchunyang, Senz, Janine, Leung, Samuel, Feil, Lukas, Pasternak, Jana, Dixon, Katherine, Hartkopf, Andreas, Krämer, Bernhard, Brucker, Sara, Heitz, Florian, du Bois, Andreas, Harter, Philipp, Kommoss, Felix K F, Sinn, Hans-Peter, Heublein, Sabine, Kommoss, Friedrich, Vollert, Hans-Walter, Manchanda, Ranjit, de Kroon, Cornelis D, Nijman, Hans W, de Bruyn, Marco, Thompson, Emily F, Bashashati, Ali, McAlpine, Jessica N, Singh, Naveena, Tinker, Anna V, Staebler, Annette, Bosse, Tjalling, Kommoss, Stefan, Köbel, Martin, Anglesio, Michael S

“…Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current…”
Get full text

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study by Domingo, Enric, Freeman-Mills, Luke, Rayner, Emily, Glaire, Mark, Briggs, Sarah, Vermeulen, Louis, Fessler, Evelyn, Medema, Jan Paul, Boot, Arnoud, Morreau, Hans, van Wezel, Tom, Liefers, Gerrit-Jan, Lothe, Ragnhild A, Danielsen, Stine A, Sveen, Anita, Nesbakken, Arild, Zlobec, Inti, Lugli, Alessandro, Koelzer, Viktor H, Berger, Martin D, Castellví-Bel, Sergi, Muñoz, Jenifer, de Bruyn, Marco, Nijman, Hans W, Novelli, Marco, Lawson, Kay, Oukrif, Dahmane, Frangou, Eleni, Dutton, Peter, Tejpar, Sabine, Delorenzi, Mauro, Kerr, Rachel, Kerr, David, Tomlinson, Ian, Church, David N

“…Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises…”
Get more information

ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors by Fan, Xiaoyu, Nijman, Hans W., de Bruyn, Marco, Elsinga, Philip H.

“…Background Immune checkpoint inhibitors (ICIs) have made significant progress in oncotherapy improving survival of patients. However, the benefits are limited…”
Get full text